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Considerable data have accumulated
which suggest that some or most forms
of periodontal disease are specific, albeit
chronic, bacteriological infections (1, 2).
In most instances the plaque flora re-
moved from infiamed sites are dominat-
ed by anaerobic organisms such as spi-
rochetes, bacteroides and eubacterium
species (1^) . In some instances, the
microaerophilic organism Actinobacil-
lus actinomycetemcomitans (Aa) has
been associated with periodontal path-
ology (5, 6). These findings indicate that
treatments aimed at controlling peri-
odontal disease could contain an anti-
microbial component directed to the re-
duction, if not the elimination of the
above periodontopathic organisms in or
from the plaque.
The choice of which antimicrobial
agent to use would depend on the bac-
terial nature of the plaque infection and
as to whether the agent is to be delivered
systemically and/or locally (1). Agents
such as metronidazole and clindamycin
would seem to be indicated when an
anaerobic infection has been document-
ed, whereas tetracyclines would be indi-
cated where an Aa infection has been
established (6, 7). Alternatively, broad
spectrum antiseptics such as chlorhex-
idine can be delivered locally to the
pocket either via irrigation (8) or slow
release delivery systems (9).
The efficacy of antimicrobial agents
can best be evaluated by the inclusion of
placebo groups and the use of a double
blind design. In a double blind (DB)
design all patients could receive the re-
quired mechanical debridement, so as
to fulfill the ethical considerations for
treatment, and then randomly receive
either placebo (positive control) or anti-
microbial medications (experimental).
The antimicrobial treatments need only
be of short duration, say 1 or 2 wk,
because this length of treatment, pro-
vided an appropriate dose is prescribed
and taken by the patient, is sufficient to
change the composition of the plaque
fiora in most instances (1, 10).
Tetracyclines and metronidazole
(Met) have been the agents most widely
studied in the treatment of periodon-
titis, but only metronidazole has been
evaluated using a DB design (8, 10). In
these studies. Met significantly in-
creased apparent attachment gain and
reduced probing depths in the deepest
probing sites relative to mechanical de-
bridement (10), or irrigation with chlor-
hexidine (8). This suggested that the sy-
stemically delivered Met was able to re-
duce or eliminate the anaerobic
infection at the base of the pocket in
ways that were not routinely achievable
with mechanical debridement or chlor-
hexidine irrigation.
The success of Met in both reducing
probing depth and in increasing appar-
ent attachment raised the possibility
that Met therapy could reduce the surgi-
cal needs of the patient with advanced
periodontitis. This was assessed using
a DB design (10) and measuring the
changes in those clinical parameters, i.e.
appearance of tissue, x-ray changes,
probing depths, apparent attachment
gain, that resulted in the clinical de-
cision to perform surgery. In this regard
each tooth that required some form of
periodontal surgery on one or more of
its aspects was considered a surgical
unit. The number of teeth requiring sur-
gery at the onset of the study and again
at the conclusion of the root surface
debridement was determined for each
patient by the same periodontist. This
individual was not aware of the treat-
ment groups that the patients were in,
was not involved in the treatment pro-
cedures, and on the second examination
was not provided access to the results of
his first examination. Thus, while these
surgical decisions had a large subjective
component and maybe were unique to
this examiner, they were obtained under
strictly bUnded conditions and reflected
the reality of the patients' subsequent
treatment, i.e. they did or did not re-
ceive surgery based upon this individu-
al's decision. It was assumed that any
changes in surgical needs between the
first and second examinations that re-
sulted from examiner error would be
equal in both groups and would not
mask a treatment effect if one existed.
Patients were selected for the study
on the basis of having at least 5 surgical
units. The pafients randomly assigned
to the Met group initially required 19.2
units of surgery and those assigned to
the placebo group required 16.6 units
of surgery. When reexamined after the
completion of scaling and root planing,
the Met patients required 10.7 units and
the placebo patients required 13.6 units.
The reduction of 8.5 units in the Met
group was significant (paired t test, p =
0.05), whereas the reduction in the pla-
cebo group was not. Covariate analysis
showed that the difference of 5.5 units
between the two groups was significant
(p = 0.05).
These data indicate that 1 wk of Met
therapy, when superimposed upon rig-
orous mechanical debridement can sig-
nificantly reduce the surgical needs of
the patient when compared to placebo
therapy plus rigorous mechanical debri-
dement. This reduction had immediate
cost and comfort benefits for the pa-
tients and would seem to be an import-
ant outcome of Met therapy. However,
it can be argued that this surgical re-
duction was only surgery delayed and
that these sites would eventually need
surgery. This issue was addressed by
maintaining the DB nature of the study
and having the same clinician reexamine
the patients during the recall visits.
The first such annual reexamination,
which occurred about 27 months after
the taking of the medication, about 20
months after the second treatment plan-
ing and 12 months after compledon of
the required surgery, showed that the
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placebo patients required on average 0.3
surgical units and 5.8 teeth that needed
to be reinstrumented, whereas the Met
patients required an average of 0.2 sur-
gical units and 3.6 teeth that needed
to be reinstrumented. Apparently, the
beneficial effects of the Met were sus-
tained as there was no increase in treat-
ment needs in the Met group relative to
the placebo group.
These clinical findings were also
evaluated by the compliance pattern
that had been observed some 27 months
earlier by the microscopic monitoring
of the spirochetal levels and proportions
in the plaque. The study had been de-
signed so that debridement was per-
formed on only one quadrant during
the period of drug administration, so
that it was possible to assess the im-
mediate effects of debridement. Met
plus debridement. Met and no treat-
ment upon the plaque levels and pro-
portions of spirochetes, i.e. organisms
uniquely sensitive to metronidazole
(11). Thus patients who received Met
and in whom the plaque levels and/or
proportions of spirochetes did not ap-
preciably decrease or actually increased
were considered to be noncompliant in
their usage of metronidazole.
Five Met patients had plaques which
showed no evidence of spirochetal re-
duction, whereas all patients who re-
ceived Met plus debridement showed re-
duction of spirochetes (Table 1). This
suggested that these 5 patients did not
derive any benefit from the Met, either
because they did not take the Met as
instructed or because they took the Met
but the prescribed dosage was too low.
As previous studies indicated that the
prescribed dosage was adequate (10), it
was assumed that these patients were
non-compliers. When the treatment
needs at the recall visit were reanalyzed
to take compliance into account, the
noncompliant patients accounted for 80
of the treatment needs observed in the
Met patients at the recall examination.
Thus patient noncomphance can ob-
scure the benefits to be derived from any
systemic antimicrobial treatment. This
problem can be minimized, if not elim-
inated, by placement of slow release de-
vices containing antimicrobial agents
Tabie 1. Compliance monitoring of systemic metronidazole as judged by change in proportions










































a) compliance assigned when % spirochetes decreased 6% or more; noncompliance assigned
when % spirochetes exhibited no change or increased.
I decreased by.
t increased by.














54.2 + 4.2 <-






p<0.001' '^ 13.6 + 3.7
a) an ethylcellulose film (N7F) containing 20% metronidazole was placed into each of 25
pockets for periods of 2 to 7 d.
b) paired t test.
directly into the periodontal pocket (9,
12, 13). We have evaluated an ethylcel-
lulose film containing 20% Met for its
ability to reduce the levels and pro-
portions of spirochetes. These films
were formulated with the N7F formu-
lation of ethylcellulose because this
polymer is FDA-approved as a food ad-
ditive, and would not be perceived as
causing any untoward effects if swal-
lowed. These brittle films were not well
retained within the pocket, but even so
they were effective in reducing plaque
levels and proportions of spirochetes
(Table 2). Films made with the NlOO
ethylcellulose have been retained for
longer periods. Thus the problem of
noncompliance would seen to be solved
by the placement of films into the
pocket which release Met in a slow but
continuous fashion.
These findings from DB studies indi-
cate that the use of Met in conjunction
with scaling and root planing provides
a significantly better clinical result, as
judged by reduced need for surgery,
than the use of scaling and root planing
alone. Patient noncompliance with sys-
temic medication can confound the re-
sults, but this problem may be resolved
by the placement of slow release films
containing Met directly into the pocket.
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